Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 26


Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK.

Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Erratum in: Lancet. 2016 Jul 30;388(10043):464.


Upper gastrointestinal diseases in patients for endoscopy in South-Western Uganda.

Obayo S, Muzoora C, Ocama P, Cooney MM, Wilson T, Probert CS.

Afr Health Sci. 2015 Sep;15(3):959-66. doi: 10.4314/ahs.v15i3.33.


National Trends of Local Ablative Therapy Among Young Patients With Small Renal Masses in the United States.

Kiechle JE, Abouassaly R, Smaldone MC, Shah ND, Dong S, Cherullo EE, Nakamoto D, Zhu H, Cooney MM, Kim SP.

Urology. 2015 Nov;86(5):962-7. doi: 10.1016/j.urology.2015.08.016.


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.

N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747.


Incidence of hypercoagulable events after image-guided percutaneous cryoablation of renal tumors: a single-center experience.

Hartman JB, Bhojwani N, Corn DJ, Cooney MM, Haaga J, Ponsky L, Abouassaly R, Paspulati A, Prologo JD.

J Vasc Interv Radiol. 2014 May;25(5):776-9. doi: 10.1016/j.jvir.2014.01.027.


Phase I trial of pomalidomide given for patients with advanced solid tumors.

Cooney MM, Nock C, Bokar J, Krishnamurthi S, Gibbons J, Rodal MB, Ness A, Remick SC, Dreicer R, Dowlati A.

Cancer Chemother Pharmacol. 2012 Nov;70(5):755-61. doi: 10.1007/s00280-012-1919-6.


Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.

Brell JM, Krishnamurthi SS, Rath L, Bokar JA, Savvides P, Gibbons J, Cooney MM, Meropol NJ, Ivy P, Dowlati A.

Cancer Chemother Pharmacol. 2012 Oct;70(4):547-53.


Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.

Lin PY, Cheng KL, McGuffin-Cawley JD, Shieu FS, Samia AC, Gupta S, Cooney M, Thompson CL, Liu CC.

Biosensors (Basel). 2012 Sep 26;2(4):377-87. doi: 10.3390/bios2040377.


A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.

Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA.

Invest New Drugs. 2012 Feb;30(1):364-7. doi: 10.1007/s10637-010-9516-1.


A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.

Nock CJ, Brell JM, Bokar JA, Cooney MM, Cooper B, Gibbons J, Krishnamurthi S, Manda S, Savvides P, Remick SC, Ivy P, Dowlati A.

Invest New Drugs. 2011 Feb;29(1):126-30. doi: 10.1007/s10637-009-9322-9.


A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R.

Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717.


A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.

Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC.

Thyroid. 2009 Mar;19(3):233-40. doi: 10.1089/thy.2008.0321.


High-grade transitional cell carcinoma and melanosis of urinary bladder: case report and review of the literature.

Sanborn SL, MacLennan G, Cooney MM, Zhou M, Ponsky LE.

Urology. 2009 Apr;73(4):928.e13-5. doi: 10.1016/j.urology.2008.05.039. Review.


Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM.

Invest New Drugs. 2009 Oct;27(5):453-60. doi: 10.1007/s10637-008-9200-x.


Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.

Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC.

Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0.


Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.

Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ; Eastern Cooperative Oncology Group..

Cancer. 2008 Jun 15;112(12):2671-5. doi: 10.1002/cncr.23503.


Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC.

Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2.


Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.

van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, Remick SC.

Curr Opin Hematol. 2007 Sep;14(5):468-80. Review.


Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

Dowlati A, Subbiah S, Cooney M, Rutherford K, Mekhail T, Fu P, Chapman R, Ness A, Cortas T, Saltzman J, Levitan N, Warren G.

Lung Cancer. 2007 Jun;56(3):377-81.


Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.

Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC.

Nat Clin Pract Oncol. 2006 Dec;3(12):682-92. Review.

Items per page

Supplemental Content

Loading ...
Support Center